sarecycline
Sign in to saveSarecycline, sold under the brand name Seysara, is a narrow-spectrum tetracycline-derived antibiotic medication. It is specifically designed for the treatment of acne, and was approved by the FDA in October 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Two randomized and well-controlled clinical trials reported efficacy data on both facial and truncal acne (back and chest). Efficacy was assessed in a total of 2002 subjects 9 years of age and older. Unlike other tetracycline-class antibiotics, sarecycline has
Key facts
- Drug.MedlinePlus
- a618068
- Drug.image
- Sarecycline.svg
- Drug.image_class
- skin-invert-image
- Drug.pronounce
- sar"e sye' kleen
- Drug.tradename
- Seysara
- Drug.DailyMedID
- Sarecycline
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- J01
- Drug.ATC_suffix
- AA14
- Drug.legal_US
- Rx-only
- Drug.index2_label
- as HCl
- Drug.CAS_number
- 1035654-66-0
- Drug.PubChem
- 54681908
- Drug.PubChem2
- 71296095
- Drug.ChemSpiderID
- 28540486
- Drug.UNII
- 94O110CX2E
- Drug.DrugBank
- DB12035
- Drug.DrugBank2
- DBSALT002125
via Wikipedia infobox
Article
3 sectionsContents
- Medical uses
- Synthesis
- References
{{Infobox drug | drug_name = | INN = | type = | image = Sarecycline.svg | image_class = skin-invert-image | alt = | caption =
| pronounce = sar"e sye' kleen | tradename = Seysara | Drugs.com = | MedlinePlus = a618068 | DailyMedID = Sarecycline | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth | class = | ATCvet = | ATC_prefix = J01 | ATC_suffix = AA14 | ATC_supplemental =